Article Contents ::
Details About Generic Salt :: Abciximab
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| 5A. ANTI-PLATELETS in 5. HEMATOLOGICAL SYSTEM |
| ABCIXIMAB |
| GLYCOPROTEIN IIB/IIIA INHIBITOR | ANTI-PLATELET |
|
Indications & Dose: ADJUNCT TO PCI IV Adult 0.25mg/kg bolus given 10-60 min before start of PCI followed by an inf of 0.125 mcg/kg/min for 12h, not to exceed inf rate of 10mcg/min | UNSTABLE ANGINA IV Adult 0.25mg/kg bolus over at least 1 min followed by an continuous inf of 0.125mcg/min for 18-24h concluding 1h post-PCI, not to exceed 10mcg/minespecially for unstable angina patients with PCI planned within 24h |
| Contra: Hypersensitivity, active major bleeding, thrombocytopenia, history of CVA (within 2 years), recent surgery of trauma, intracranial tumor, vasculitis, severe uncontrolled HTN, concomitant use of other parenteral GP IIb/IIIa inhibitor, PUD
Precautions: when used with thrombolytic agents ADR: Serious: Hypotension, chest pain, minor hemorrhage, major hemorrhage, bradycardia, peripheral edema, Others: abdominal pain, thrombocytopenia, pain at inj site, Nausea, antibody development DDI: Serious Thrombolytics Monitor: CBC, PT, APTT, and InternationalProthrombin time, activated partial thromboplastin time, hemoglobin, hematocrit, platelet count, fibrinogen, fibrin split products, transfusion requirements, signs of hypersensitivity reactions, guaiac stools, platelet count at baseline |
